Contact
Please use this form to send email to PR contact of this press release:
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
TO:
Please use this form to send email to PR contact of this press release:
argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy
TO: